Literature DB >> 8557710

Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase D.

P Friedman1, R Haimovitz, O Markman, M F Roberts, M Shinitzky.   

Abstract

Phospholipase D from Streptomyces chromofuscus hydrolyzes lysophosphatidylcholine or lysophosphatidylethanolamine in aqueous 1% Triton X-100 solution. In situ monitoring of this reaction by 31P NMR revealed the formation of cyclic lysophosphatidic acid (1-acyl 2,3-cyclic glycerophosphate) as an intermediate which was hydrolyzed further by the enzyme at a functionally distinct active site to lysophosphatidic acid (lyso-PA). Synthetic cyclic lyso-PA (1-octanoyl 2,3-cyclic glycerophosphate) was found to be stable in aqueous neutral solutions at room temperature. It was hydrolyzed by the bacterial phospholipase D to lyso-PA at a rate which was approximately 4-fold slower than the rate of formation of cyclic lyso-PA. The addition of 5-10 mM sodium vanadate could partially inhibit the ring opening reaction and thus increase substantially the cyclic lyso-PA accumulation. Cyclic lyso-PA may act as a dormant configuration of the physiologically active lyso-PA or may even possess specific activities which await verification.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557710     DOI: 10.1074/jbc.271.2.953

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.

Authors:  Daniel L Baker; Yuko Fujiwara; Kathryn R Pigg; Ryoko Tsukahara; Susumu Kobayashi; Hiromu Murofushi; Ayako Uchiyama; Kimiko Murakami-Murofushi; Eunjin Koh; Russell W Bandle; Hoe-Sup Byun; Robert Bittman; Dominic Fan; Mandi Murph; Gordon B Mills; Gabor Tigyi
Journal:  J Biol Chem       Date:  2006-06-16       Impact factor: 5.157

2.  Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid.

Authors:  Tamotsu Tsukahara; Ryoko Tsukahara; Yuko Fujiwara; Junming Yue; Yunhui Cheng; Huazhang Guo; Alyssa Bolen; Chunxiang Zhang; Louisa Balazs; Fabio Re; Guangwei Du; Michael A Frohman; Daniel L Baker; Abby L Parrill; Ayako Uchiyama; Tetsuyuki Kobayashi; Kimiko Murakami-Murofushi; Gabor Tigyi
Journal:  Mol Cell       Date:  2010-08-13       Impact factor: 17.970

3.  Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid.

Authors:  Ayako Uchiyama; Mutsuko Mukai; Yuko Fujiwara; Susumu Kobayashi; Nobuyuki Kawai; Hiromu Murofushi; Masahiro Inoue; Shigenori Enoki; Yuichiro Tanaka; Tamotsu Niki; Tetsuyuki Kobayashi; Gabor Tigyi; Kimiko Murakami-Murofushi
Journal:  Biochim Biophys Acta       Date:  2006-10-14

Review 4.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 5.  Cyclic phosphatidic acid - a unique bioactive phospholipid.

Authors:  Yuko Fujiwara
Journal:  Biochim Biophys Acta       Date:  2008-05-23

6.  Phospholipase D toxins of brown spider venom convert lysophosphatidylcholine and sphingomyelin to cyclic phosphates.

Authors:  Daniel M Lajoie; Pamela A Zobel-Thropp; Vlad K Kumirov; Vahe Bandarian; Greta J Binford; Matthew H J Cordes
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

Review 7.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.